Retavase Reteplase recombinant - Rapid Reperfusion With Fixed Dosing For the Way You Treat AMI Today Retavase Flows With You™
Prompt Intervention | Prehospital Administration | In Vitro Data | Rapid Reperfusion | Safety Information | Convenient Fixed Dosing | Contact Information | Prescribing Information
Prompt Intervention Is Imperative
ACC/AHA 2004 STEMI practice guidelines recommend appropriate and timely use of reperfusion therapy
Patients with STEMI require reperfusion therapy administered within appropriate timing guidelines and without delay. Acceptable therapeutic options include the following1:
Patients with STEMI require reperfusion therapy administered within appropriate timing guidelines and without delay. Acceptable therapeutic options include the following
Initiation of fibrinolytic therapy achieved within 30 minutes of medical contact1
ACC/AHA 2004 STEMI practice guidelines recommend appropriate and timely use of reperfusion therapy
PCI within 90 minutes of medical contact1
Situations Where Fibrinolytic Therapy Is Generally Preferred*1
Invasive strategy is not an option
–  
Catheterization lab not within hours of operation
–  
Catheterization lab occupied to capacity
–  
Lack of access to appropriately experienced staff
–  
Vascular access difficulties
Delay to invasive strategy
–  
Prolonged transport
–  
Door-to-balloon time exceeds 90 minutes
Retavase is indicated for use in the management of acute myocardial infarction (AMI) in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure, and the reduction of mortality associated with AMI. Treatment should be initiated as soon as possible after the onset of AMI symptoms.
Time is the key determinant in deciding to transfer the patient
Retavase - Time is the key determinant in deciding to transfer the patient
Longer times to treatment are inversely related to outcome with both fibrinolytic therapy and PCI2
Retavase is indicated for use in the management of acute myocardial infarction (AMI) in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure, and the reduction of mortality associated with AMI. Treatment should be initiated as soon as possible after the onset of AMI symptoms.
Over 75% of acute-care hospitals in the United States do not have PCI programs available (data collected in 2000, published in 2005)2
Retavase is indicated for use in the management of acute myocardial infarction (AMI) in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure, and the reduction of mortality associated with AMI. Treatment should be initiated as soon as possible after the onset of AMI symptoms.
Excessive delays associated with interhospital transfer for primary PCI may reduce its advantage when compared with on-site fibrinolytic therapy2
Time is the key determinant in deciding to transfer the patient
Retavase is indicated for use in the management of acute myocardial infarction (AMI) in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure, and the reduction of mortality associated with AMI. Treatment should be initiated as soon as possible after the onset of AMI symptoms.
Median time from initial hospital arrival to the first balloon inflation was 180 minutes2
Retavase is indicated for use in the management of acute myocardial infarction (AMI) in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure, and the reduction of mortality associated with AMI. Treatment should be initiated as soon as possible after the onset of AMI symptoms.
Hospitals without PCI capability should consider their total door-to-balloon times when deciding between transfer PCI and on-site fibrinolytic strategies2
*Provided fibrinolytic treatment is not contraindicated and will be administered within 3 hours of symptom onset.
†National Registry of Myocardial Infarction (NRMI)-3/4 Analysis, a multicenter study measuring total door-to-balloon times in 4278 transfer patients undergoing PCI at 419 hospitals.
Important Safety Information
Because thrombolytic therapy increases the risk of bleeding, including internal bleeding (such as intracranial, retroperitoneal, gastrointestinal, genitourinary, or respiratory), Retavase should be used only in those patients for whom its use is indicated in the prescribing information (see "Indications" in the prescribing information). In addition, thrombolytic therapy increases the absolute risk of stroke, including hemorrhagic stroke, in patients of advanced age. Cholesterol embolism has been reported rarely in patients treated with thrombolytic agents. Coronary thrombolysis may result in arrhythmias associated with reperfusion (see "Warnings" in the prescribing information).
References: 1. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction–executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004;44:671–719. 2. Nallamothu BK, Bates ER, Herrin J, et al. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation. 2005;111:761–767.
Please see full prescribing information.
    Marketed By  
   

© EKR Therapeutics, Inc. All rights reserved. January 2010.